Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on December 8, 2016. The filing discloses the entry into a material definitive agreement and provides Regulation FD disclosure regarding new government contracts and re-established financial guidance.
Key Financial Metrics and Contract Values
The filing does not provide historical revenue, profit, cash flow, or balance sheet metrics. The primary financial data disclosed relates to new contractual obligations:
- CDC Contract: A follow-on contract with the Centers for Disease Control and Prevention (CDC) to supply approximately 29.4 million doses of BioThrax over five years. The total value is up to $911 million.
- BARDA Notice of Intent: A notice of intent from the Biomedical Advanced Research and Development Authority (BARDA) to procure approximately $100 million of BioThrax for delivery within 24 months of contract award.
Material Changes and Outlook
The company announced the re-establishment of its 2016 financial guidance, though specific numerical targets for revenue or earnings are not detailed in this filing text. Initial deliveries under the new CDC contract are expected to commence in 2017, continuing through September 2021, subject to funding availability.
Risks, Contingencies, and Management Commentary
Management highlighted several risks and contingencies associated with the forward-looking statements and contracts:
- Government Termination: The CDC contract allows the government to terminate for convenience at any time, suspend work, or audit and disallow costs.
- Funding Dependency: Deliveries are subject to the availability of government appropriations and funding.
- Regulatory and Operational Risks: Risks include the ability to secure Emergency Use Authorization (EUA) or licensure for NuThrax, maintain cGMP compliance, and achieve operational efficiencies.
- Legal Proceedings: The filing references a class action lawsuit filed against the company.
- Contract Finalization: The BARDA procurement is currently a notice of intent, not a finalized contract.
Investor Verification Checklist
- Verify the specific numerical targets for the re-established 2016 financial guidance in the attached press release (Exhibit 99).
- Confirm the status of the BARDA notice of intent and the timeline for converting it into a definitive contract.
- Review the terms of the CDC contract regarding termination for convenience and cost reimbursement liabilities.
- Assess the impact of the ongoing class action lawsuit on the company's financial condition.
- Monitor the availability of government appropriations required to fund the $911 million CDC contract.